RE:RE:Oncology market is Big. 66% of BMY revenue
The MUK eleven trial in multiple myeloma was terminated by BMS once it acquired Celgene, so ONCY pivoted to carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®) which demonstrated a clinical and anti-tumor inflammatory response induced with pelareorep-carfilzomib treatment in this extremely difficult to treat patient population with an 50% overall response rate and 83% Clinical Benefit Rate in patients who failed carfilzomib.
There is much you don't know about this stock Mr.Un-Notable